SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
We’re going down soon, to move to a new Data Center today. We’ll be up ASAP. Sorry. |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/09/23 ReShape Lifesciences Inc. 10-Q 9/30/23 60:6.2M Toppan Merrill Bridge/FA |
Document/Exhibit Description Pages Size 1: 10-Q Quarterly Report HTML 1.71M 2: EX-31.1 Certification -- §302 - SOA'02 HTML 22K 3: EX-31.2 Certification -- §302 - SOA'02 HTML 22K 4: EX-32.1 Certification -- §906 - SOA'02 HTML 21K 5: EX-32.2 Certification -- §906 - SOA'02 HTML 20K 11: R1 Document and Entity Information HTML 69K 12: R2 Condensed Consolidated Balance Sheets HTML 119K 13: R3 Condensed Consolidated Balance Sheets HTML 40K (Parenthetical) 14: R4 Condensed Consolidated Statements of Operations HTML 97K 15: R5 Condensed Consolidated Statements of Comprehensive HTML 41K Loss 16: R6 Condensed Consolidated Statements of Stockholders' HTML 79K Equity 17: R7 Condensed Consolidated Statements of Cash Flows HTML 109K 18: R8 Basis of Presentation HTML 39K 19: R9 Liquidity and Management's Plans HTML 25K 20: R10 Supplemental Balance Sheet Information HTML 66K 21: R11 Intangible Assets HTML 41K 22: R12 Leases HTML 53K 23: R13 Equity HTML 33K 24: R14 Warrants HTML 45K 25: R15 Revenue Disaggregation and Operating Segments HTML 48K 26: R16 Income Taxes HTML 23K 27: R17 Stock-based Compensation HTML 102K 28: R18 Commitment and Contingencies HTML 23K 29: R19 Subsequent Events HTML 24K 30: R20 Basis of Presentation (Policies) HTML 52K 31: R21 Basis of Presentation (Tables) HTML 28K 32: R22 Supplemental Balance Sheet Information (Tables) HTML 69K 33: R23 Intangible Assets (Tables) HTML 38K 34: R24 Leases (Tables) HTML 53K 35: R25 Warrants (Tables) HTML 43K 36: R26 Revenue Disaggregation and Operating Segments HTML 44K (Tables) 37: R27 Stock-based Compensation (Tables) HTML 100K 38: R28 Basis of Presentation - Long-Lived Assets HTML 23K (Details) 39: R29 Basis of Presentation - (Details) HTML 32K 40: R30 Liquidity and Management Plans (Details) HTML 29K 41: R31 Supplemental Balance Sheet Information (as HTML 59K Restated) (Details) 42: R32 Intangible Assets (Details) HTML 46K 43: R33 Leases - Supplemental Information (Details) HTML 41K 44: R34 Leases - Maturities of Liabilities (Details) HTML 37K 45: R35 Equity (Details) HTML 104K 46: R36 Warrants (Details) HTML 88K 47: R37 Warrants - Black-Scholes Option Pricing Model HTML 40K (Details) 48: R38 Warrants - Fair Value of Warrant Liabilities HTML 28K (Details) 49: R39 Revenue Disaggregation and Operating Segments HTML 38K (Details) 50: R40 Income Taxes (Details) HTML 24K 51: R41 Stock-based Compensation - Stock-based HTML 27K compensation expense (Details) 52: R42 Stock-based Compensation - Stock Option Activity HTML 65K (Details) 53: R43 Stock-based Compensation - Restricted Stock Units HTML 40K (Details) 54: R44 Commitments and Contingencies (Details) HTML 37K 55: R45 Subsequent Events (Details) HTML 67K 58: XML IDEA XML File -- Filing Summary XML 102K 56: XML XBRL Instance -- rsls-20230930x10q_htm XML 1.37M 57: EXCEL IDEA Workbook of Financial Report Info XLSX 98K 7: EX-101.CAL XBRL Calculations -- rsls-20230930_cal XML 142K 8: EX-101.DEF XBRL Definitions -- rsls-20230930_def XML 525K 9: EX-101.LAB XBRL Labels -- rsls-20230930_lab XML 945K 10: EX-101.PRE XBRL Presentations -- rsls-20230930_pre XML 737K 6: EX-101.SCH XBRL Schema -- rsls-20230930 XSD 121K 59: JSON XBRL Instance as JSON Data -- MetaLinks 360± 552K 60: ZIP XBRL Zipped Folder -- 0001558370-23-018344-xbrl Zip 272K
Exhibit 31.1
CERTIFICATION
I, Paul F. Hickey, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of ReShape Lifesciences Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the consolidated financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
| |
| /S/ paul F. hickey |
| Paul F. Hickey |
| President and Chief Executive Officer |
Date: November 8, 2023
No
This ‘10-Q’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed as of: | 11/9/23 | 8-K | ||
Filed on: | 11/8/23 | 4, 8-K | ||
For Period end: | 9/30/23 | |||
List all Filings |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 10/05/23 ReShape Lifesciences Inc. 8-K:1,7,9 9/29/23 12:331K Toppan Merrill/FA 9/22/23 ReShape Lifesciences Inc. 8-K:1,8,9 9/19/23 12:465K Toppan Merrill/FA 4/26/23 ReShape Lifesciences Inc. 8-K:1,3,8,9 4/20/23 15:773K Toppan Merrill/FA |